ODAC Proves a Harsh Critic of Amgen's Xgeva in CRPC
By Mari Serebrov
Thursday, February 9, 2012
"Show me the benefit" was the mantra Wednesday when an FDA advisory committee critiqued the ability of Amgen Inc.'s Xgeva to prolong the time until bone metastasis in men with castration-resistant prostate cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.